Pancreatic Cancer Clinical Trial Landscape
Data updated: May 20, 2026
1,539 clinical trials tracked since 2008
Pancreatic cancer is a disease in which malignant cells form in the tissues of the pancreas, an organ located behind the stomach. While relatively rare, it is often diagnosed at later stages, making treatment challenging. The clinical trial landscape for pancreatic cancer is active, with 1,527 trials registered since 2008, and 642 currently active (recruiting, enrolling, or active but not recruiting). Activity is heavily concentrated in early-phase trials, with 315 active Phase 1 trials out of 787 total, and 415 active Phase 2 trials out of 921 total. Phase 3 trials account for 70 active trials out of 133 total, while Phase 4 trials are less common, with only 10 active trials out of 23 total. Revolution Medicines, Inc. leads industry sponsorship with 9 active trials, followed by AstraZeneca (7 active), Astellas Pharma Global Development, Inc. (6 active), Seagen, a wholly owned subsidiary of Pfizer (6 active), and Eli Lilly (4 active). The high volume of Phase 1 and 2 trials suggests a strong focus on novel therapeutic approaches and early-stage drug development in this indication.
641 active
/
1539 total (since 2008)
320
Phase 1 Active
798 total
410
Phase 2 Active
923 total
70
Phase 3 Active
133 total
11
Phase 4 Active
24 total
Top Industry Sponsors
Sorted by active Active Done Failed
Revolution Medicines, Inc. 9 0 0
AstraZeneca 7 7 1
Astellas Pharma Global Development, Inc. 6 0 0
Seagen, a wholly owned subsidiary of Pfizer 5 0 1
Eli Lilly 4 7 1
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06989437 RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer n=982
NCT06608927 ACTIVE NOT RECRUITING
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Arcus Biosciences, Inc. n=610
NCT07562152 RECRUITING
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Immuneering Corporation n=510
NCT07219238 RECRUITING
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare n=175
NCT06958328 RECRUITING
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NRG Oncology n=356
+ 128 more Phase 3 trials — see full database below
Pancreatic Cancer — Trials Started by Year (last 10 years)
2016 80
2017 78
2018 79
2019 79
2020 76
2021 102
2022 82
2023 115
2024 139
2025 155
2026 84
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Revolution Medicines, Inc. 9
AstraZeneca 15
Astellas Pharma Global Development, Inc. 6
Seagen, a wholly owned subsidiary of Pfizer 6
Eli Lilly 12
Bristol-Myers Squibb 9
Akeso 4
Jiangsu HengRui Medicine Co., Ltd. 8
AbbVie 4
Qilu Pharmaceutical Co., Ltd. 4
Active Trials by Phase
Phase 1 320
Phase 2 410
Phase 3 70
Phase 4 11
Enrollment Size Distribution
1-50 825
51-200 450
201-500 133
501-1k 54
1k+ 2
All Industry Sponsors
Sorted by active Active Done Failed
Revolution Medicines, Inc. 9 0 0
AstraZeneca 7 7 1
Astellas Pharma Global Development, Inc. 6 0 0
Seagen, a wholly owned subsidiary of Pfizer 5 0 1
Eli Lilly 4 7 1
Bristol-Myers Squibb 4 5 0
Akeso 4 0 0
Jiangsu HengRui Medicine Co., Ltd. 3 4 1
AbbVie 3 0 1
Qilu Pharmaceutical Co., Ltd. 3 1 0
CARsgen Therapeutics Co., Ltd. 3 1 0
Chipscreen Biosciences, Ltd. 3 0 0
Pfizer 2 5 5
Novartis 2 5 5
ImmunityBio, Inc. 2 1 5
NCT06989437 RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer n=982
NCT06608927 ACTIVE NOT RECRUITING
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Arcus Biosciences, Inc. n=610
NCT07562152 RECRUITING
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Immuneering Corporation n=510
NCT07219238 RECRUITING
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare n=175
NCT06958328 RECRUITING
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NRG Oncology n=356
NCT07252232 RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines, Inc. n=500
NCT07076121 RECRUITING
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Bristol-Myers Squibb n=470
NCT06625320 ACTIVE NOT RECRUITING
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines, Inc. n=500
NCT07217717 RECRUITING
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
SOFIE n=200
NCT07409272 RECRUITING
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Global Development, Inc. n=614
NCT07491445 RECRUITING
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Revolution Medicines, Inc. n=900
NCT06998940 RECRUITING
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network n=94
NCT07490301 NOT YET RECRUITING
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
AbbVie n=900
NCT06953999 RECRUITING
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Akeso n=999
NCT07445295 NOT YET RECRUITING
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Chipscreen Biosciences, Ltd. n=558
NCT05836870 ACTIVE NOT RECRUITING
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
M.D. Anderson Cancer Center n=58
NCT07436741 NOT YET RECRUITING
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital n=106
NCT07429643 NOT YET RECRUITING
Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.
Assiut University n=20
NCT07044453 RECRUITING
Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX
University Hospital, Rouen n=390
NCT04340141 ACTIVE NOT RECRUITING
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Alliance for Clinical Trials in Oncology n=358
NCT06752811 RECRUITING
Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Shanghai Yizhong Pharmaceutical Co., Ltd. n=416
NCT07383922 NOT YET RECRUITING
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
FutureGen Biopharmaceutical (Beijing) Co., Ltd n=524
NCT06861088 RECRUITING
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Quercis Pharma AG n=480
NCT07336953 NOT YET RECRUITING
A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)
West China Hospital n=198
NCT06115499 ACTIVE NOT RECRUITING
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology n=10
NCT06361888 RECRUITING
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed n=502
NCT07165951 RECRUITING
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. n=566
NCT07272109 NOT YET RECRUITING
Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes
Fudan University n=210
NCT07238283 RECRUITING
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd. n=662
NCT06783140 RECRUITING
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
University Health Network, Toronto n=10
NCT07262567 NOT YET RECRUITING
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc. n=320
NCT07232875 NOT YET RECRUITING
HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd. n=588
NCT03257033 RECRUITING
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
RenovoRx n=190
NCT07079228 RECRUITING
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd. n=602
NCT07155525 RECRUITING
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
Minia University n=194
NCT07155629 NOT YET RECRUITING
Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer
Helsinki University Central Hospital n=381
NCT07081360 RECRUITING
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Minia University n=262
NCT07138846 NOT YET RECRUITING
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
Lepu Biopharma Co., Ltd. n=231
NCT07066098 RECRUITING
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Innovent Biologics (Suzhou) Co. Ltd. n=201
NCT06018883 ACTIVE NOT RECRUITING
Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer
Fudan University n=100
NCT06095141 RECRUITING
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
Fudan University n=30
NCT06250972 RECRUITING
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
Fudan University n=210
NCT07098598 RECRUITING
Pancreatic Cancer Diagnosis With FAPI-PET Imaging
Turku University Hospital n=100
NCT06999512 NOT YET RECRUITING
Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer
Assistance Publique - Hôpitaux de Paris n=526
NCT06897644 RECRUITING
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
Gruppo Oncologico del Nord-Ovest n=340
NCT05482516 RECRUITING
Evaluating Novel Therapies in ctDNA Positive GI Cancers
Georgetown University n=20
NCT06946420 ACTIVE NOT RECRUITING
SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=108
NCT05653453 RECRUITING
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd n=512
NCT03899636 ACTIVE NOT RECRUITING
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Angiodynamics, Inc. n=528
NCT06782412 RECRUITING
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
KU Leuven n=109
NCT06427447 RECRUITING
Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
Changhai Hospital n=770
NCT01954992 RECRUITING
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Eleison Pharmaceuticals LLC. n=480
NCT05314998 NOT YET RECRUITING
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
John Neoptolemos n=394
NCT06714604 RECRUITING
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
Sahlgrenska University Hospital n=432
NCT05529940 RECRUITING
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
Seoul National University Hospital n=609
NCT06601283 RECRUITING
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
Fudan University n=50
NCT06598033 RECRUITING
Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
Fudan University n=50
NCT02919787 ACTIVE NOT RECRUITING
Nordic Pancreatic Cancer Trial (NorPACT) - 1
Oslo University Hospital n=140
NCT05254171 RECRUITING
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Panbela Therapeutics, Inc. n=600
NCT04927780 ACTIVE NOT RECRUITING
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
Erasmus Medical Center n=378
NCT06571461 NOT YET RECRUITING
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
CSPC Ouyi Pharmaceutical Co., Ltd. n=408
NCT06079346 RECRUITING
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Oncotelic Inc. n=455
NCT06492941 NOT YET RECRUITING
A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=142
NCT06409429 NOT YET RECRUITING
Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital n=146
NCT05751850 RECRUITING
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd. n=778
NCT06391892 RECRUITING
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
Elisabethinen Hospital n=100
NCT06217042 NOT YET RECRUITING
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
Fudan University n=524
NCT06017284 RECRUITING
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
Fudan University n=100
NCT05268692 RECRUITING
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
Kochi University n=500
NCT04969731 RECRUITING
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
GC Cell Corporation n=408
NCT05131776 TERMINATED
EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma.
Chinese University of Hong Kong n=2
NCT01013649 COMPLETED
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
National Cancer Institute (NCI) n=546
NCT03943667 COMPLETED
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
UNICANCER n=211
NCT03269994 COMPLETED
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
Memorial Sloan Kettering Cancer Center n=967
NCT03434678 COMPLETED
Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
Memorial Sloan Kettering Cancer Center n=133
NCT00806611 COMPLETED
Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University n=438
NCT03750669 COMPLETED
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University n=324
NCT01746979 COMPLETED
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
ImmunoGenesis n=693
NCT03468335 COMPLETED
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
AIO-Studien-gGmbH n=151
NCT03984214 COMPLETED
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
Arbeitsgemeinschaft medikamentoese Tumortherapie n=109
NCT04229004 COMPLETED
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
Pancreatic Cancer Action Network n=502
NCT02457156 COMPLETED
Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy
University of Liverpool n=295
NCT02349412 COMPLETED
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology n=405
NCT04935359 COMPLETED
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
Novartis Pharmaceuticals n=511
NCT03512756 TERMINATED
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc n=130
NCT03941093 COMPLETED
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Kyntra Bio n=284
NCT01231347 COMPLETED
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
NantCell, Inc. n=800
NCT01827553 COMPLETED
Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy
University of Erlangen-Nürnberg Medical School n=830
NCT02395016 COMPLETED
A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
Biotech Pharmaceutical Co., Ltd. n=90
NCT04300114 TERMINATED
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd. n=5
NCT02539537 COMPLETED
A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
UNICANCER n=171
NCT04592861 TERMINATED
Carbon Ion RT for Locally Advanced Pancreatic Cancer
Albert Einstein College of Medicine n=5
NCT04329949 TERMINATED
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Corcept Therapeutics n=43
NCT05074589 COMPLETED
Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd. n=298
NCT02101021 TERMINATED
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Sierra Oncology LLC - a GSK company n=25
NCT03126435 COMPLETED
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
SynCore Biotechnology Co., Ltd. n=218
NCT02948309 COMPLETED
Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer
Karolinska University Hospital n=290
NCT03504423 COMPLETED
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Cornerstone Pharmaceuticals n=528
NCT01926197 COMPLETED
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Stanford University n=27
NCT03665441 COMPLETED
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
ERYtech Pharma n=512
NCT01526135 COMPLETED
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma
UNICANCER n=493
NCT03673137 COMPLETED
Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC
Fuda Cancer Hospital, Guangzhou n=120
NCT01956812 TERMINATED
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
Gilead Sciences n=334
NCT03536182 WITHDRAWN
Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
University of Texas Southwestern Medical Center
NCT04151719 WITHDRAWN
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Bausch Health Americas, Inc.
NCT04083651 WITHDRAWN
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Bausch Health Americas, Inc.
NCT03649035 WITHDRAWN
Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma
Istituto Clinico Humanitas
NCT02195232 COMPLETED
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
Jeffrey Zwicker, MD n=64
NCT02436668 COMPLETED
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Pharmacyclics LLC. n=430
NCT02340728 COMPLETED
Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies
Memorial Sloan Kettering Cancer Center n=24
NCT02923921 COMPLETED
Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company n=567
NCT01072981 COMPLETED
Immunotherapy Study for Surgically Resected Pancreatic Cancer
NewLink Genetics Corporation n=722
NCT01836432 TERMINATED
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
NewLink Genetics Corporation n=302
NCT01438476 COMPLETED
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas
M.D. Anderson Cancer Center n=178
NCT00844649 COMPLETED
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Celgene n=861
NCT01314027 TERMINATED
Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer
University of Zurich n=38
NCT02404363 TERMINATED
Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy
Assistance Publique - Hôpitaux de Paris n=39
NCT02117479 TERMINATED
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Incyte Corporation n=321
NCT03239184 COMPLETED
Bioinformation Therapy for Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou n=120
NCT00789633 COMPLETED
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
AB Science n=353
NCT01900327 TERMINATED
Neoadjuvant Treatment in Resectable Pancreatic Cancer
Universitätsklinikum Hamburg-Eppendorf n=32
NCT01458717 COMPLETED
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
Seoul National University Hospital n=58
NCT02284139 COMPLETED
Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects
Dong-A University Hospital n=90
NCT02988635 COMPLETED
Early Palliative Care on Quality of Life of Advanced Cancer Patients
Azienda Ospedaliero-Universitaria di Parma n=281
NCT01360853 COMPLETED
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Traws Pharma, Inc. n=160
NCT01494506 COMPLETED
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
Merrimack Pharmaceuticals n=417
NCT00994110 COMPLETED
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Memorial Sloan Kettering Cancer Center n=439
NCT00634725 COMPLETED
Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
GERCOR - Multidisciplinary Oncology Cooperative Group n=820
NCT01598584 WITHDRAWN
Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT01419002 TERMINATED
Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer
CHIR-Net n=5
NCT01362582 TERMINATED
Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer
National Center for Tumor Diseases, Heidelberg n=32
NCT04172532 RECRUITING
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
NCT05554367 ACTIVE NOT RECRUITING
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
NCT04548752 ACTIVE NOT RECRUITING
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
National Cancer Institute (NCI)
NCT04550494 RECRUITING
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
NCT07578337 NOT YET RECRUITING
A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.
Nelum Corp
NCT04858334 RECRUITING
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
National Cancer Institute (NCI)
NCT01972919 ACTIVE NOT RECRUITING
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
Medical College of Wisconsin
NCT07529808 NOT YET RECRUITING
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
BigHat Biosciences, Inc.
NCT01174121 RECRUITING
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Cancer Institute (NCI)
NCT07575191 NOT YET RECRUITING
Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
Smartwise Sweden AB
NCT05922930 RECRUITING
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
M.D. Anderson Cancer Center
NCT04083599 ACTIVE NOT RECRUITING
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT03523312 ACTIVE NOT RECRUITING
Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT06239194 RECRUITING
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT04789486 RECRUITING
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
Dana-Farber Cancer Institute
NCT06094140 ACTIVE NOT RECRUITING
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
Australasian Gastro-Intestinal Trials Group
NCT03652428 RECRUITING
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
University of Maryland, Baltimore
NCT07076212 RECRUITING
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
Medical University of South Carolina
NCT06941857 RECRUITING
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07026279 ACTIVE NOT RECRUITING
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
Amplia Therapeutics Limited
NCT04851119 RECRUITING
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
NCT04233866 ACTIVE NOT RECRUITING
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
ECOG-ACRIN Cancer Research Group
NCT06503146 RECRUITING
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT07565155 NOT YET RECRUITING
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency
Peter Hosein, MD
NCT07563738 RECRUITING
A 2-part Phase 1/2 Open-label Trial on ODM-212
Orion Corporation, Orion Pharma
NCT04421820 RECRUITING
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
NCT05933265 ACTIVE NOT RECRUITING
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
NCT07561463 NOT YET RECRUITING
Sacituzumab Tirumotecan for Pancreatic Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT02498613 ACTIVE NOT RECRUITING
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
NCT07157033 RECRUITING
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
Xerient Pharma
NCT06305247 ACTIVE NOT RECRUITING
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT06710756 RECRUITING
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT07478523 RECRUITING
FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers
University Hospital, Bordeaux
NCT07214298 RECRUITING
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
NCT04887805 ACTIVE NOT RECRUITING
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
NCT06710132 RECRUITING
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
EMD Serono Research & Development Institute, Inc.
NCT07255404 RECRUITING
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
BioNTech SE
NCT06844422 RECRUITING
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
Shandong Cancer Hospital and Institute
NCT05988918 ACTIVE NOT RECRUITING
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
NCT03190941 RECRUITING
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT05985655 RECRUITING
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT06128551 RECRUITING
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
NCT03682289 ACTIVE NOT RECRUITING
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Rahul Aggarwal
NCT06483555 RECRUITING
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
UNC Lineberger Comprehensive Cancer Center
NCT07450859 RECRUITING
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
BicycleTx Limited
NCT06423326 RECRUITING
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
NCT07020221 RECRUITING
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
NCT06922591 RECRUITING
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics, Inc.
NCT07542002 RECRUITING
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
Ningbo Medical Center Lihuili Hospital
NCT07539155 NOT YET RECRUITING
Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer
University of Arkansas
NCT03301805 NOT YET RECRUITING
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
Rgene Corporation
NCT03485209 ACTIVE NOT RECRUITING
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT07444541 NOT YET RECRUITING
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
NCT04940286 ACTIVE NOT RECRUITING
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
NCT06453486 RECRUITING
A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment
University Health Network, Toronto
NCT07283705 RECRUITING
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
M.D. Anderson Cancer Center
NCT07488676 RECRUITING
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Astellas Pharma Global Development, Inc.
NCT07126158 RECRUITING
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
NCT06659705 RECRUITING
Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)
Institut Curie
NCT07353645 RECRUITING
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT05065801 RECRUITING
Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients
Institut du Cancer de Montpellier - Val d'Aurelle
NCT07438106 RECRUITING
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
NCT04895709 RECRUITING
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT07223047 RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
NCT07114861 RECRUITING
The KN510713 Study in Combination With mFOLFIRINOX
New Cancer Cure-Bio Co.,Ltd.
NCT05257993 RECRUITING
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
Onconic Therapeutics Inc.
NCT05053971 RECRUITING
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
National Cancer Institute (NCI)
NCT05077800 ACTIVE NOT RECRUITING
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Colin D. Weekes, M.D., PhD
NCT06790602 RECRUITING
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
University of California, San Diego
NCT05945823 ACTIVE NOT RECRUITING
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
NCT06695845 RECRUITING
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT05624918 RECRUITING
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Ashish Manne
NCT02830724 RECRUITING
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Cancer Institute (NCI)
NCT03678883 ACTIVE NOT RECRUITING
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
NCT06850623 RECRUITING
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
EXACT Therapeutics AS
NCT04820179 ACTIVE NOT RECRUITING
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
University of Arizona
NCT06445062 RECRUITING
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
NCT06821997 RECRUITING
NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Roswell Park Cancer Institute
NCT07504263 NOT YET RECRUITING
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Recurv Pharma Inc
NCT07504471 RECRUITING
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
Ruijin Hospital
NCT06904378 RECRUITING
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
NCT07483983 RECRUITING
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
Gustave Roussy, Cancer Campus, Grand Paris
NCT07432633 RECRUITING
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
NCT05825066 RECRUITING
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Wake Forest University Health Sciences
NCT07483554 NOT YET RECRUITING
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT07480928 RECRUITING
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Beijing Biotech
NCT07163273 RECRUITING
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Northwell Health
NCT06412510 RECRUITING
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
NCT04657068 RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
NCT06244771 RECRUITING
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Frontier Medicines Corporation
NCT06492915 ACTIVE NOT RECRUITING
Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Chipscreen Biosciences, Ltd.
NCT03384238 RECRUITING
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
George Poultsides
NCT05726864 ACTIVE NOT RECRUITING
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Elicio Therapeutics
NCT07477418 NOT YET RECRUITING
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)
University of Vermont
NCT07475234 NOT YET RECRUITING
Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma
Xiuchao Wang
NCT06479239 RECRUITING
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
University of Virginia
NCT07469956 NOT YET RECRUITING
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sun Yat-sen University
NCT06008288 RECRUITING
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Allist Pharmaceuticals, Inc.
NCT03816163 ACTIVE NOT RECRUITING
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Astellas Pharma Global Development, Inc.
NCT07435038 NOT YET RECRUITING
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Betta Pharmaceuticals Co., Ltd.
NCT06821503 RECRUITING
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06646055 ACTIVE NOT RECRUITING
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Akeso
NCT07199764 RECRUITING
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
University of Pennsylvania
NCT02568267 ACTIVE NOT RECRUITING
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT06895031 RECRUITING
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Guangzhou JOYO Pharma Co., Ltd
NCT04683315 RECRUITING
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
Medical College of Wisconsin
NCT07114315 RECRUITING
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Akeso
NCT07446270 NOT YET RECRUITING
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
Chinese PLA General Hospital
NCT07049055 RECRUITING
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Engeneic Pty Limited
NCT06048484 RECRUITING
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Gulam Manji
NCT03483038 ACTIVE NOT RECRUITING
A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma
University of Florida
NCT07006077 RECRUITING
Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Hangzhou Converd Co., Ltd.
NCT05642962 ACTIVE NOT RECRUITING
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Memorial Sloan Kettering Cancer Center
NCT04605913 RECRUITING
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Mayo Clinic
NCT06005493 RECRUITING
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
AstraZeneca
NCT04644068 ACTIVE NOT RECRUITING
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT07410676 RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Essen Biotech
NCT04666740 ACTIVE NOT RECRUITING
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
Memorial Sloan Kettering Cancer Center
NCT07030257 RECRUITING
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
NCT07410494 RECRUITING
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Essen Biotech
NCT07415525 NOT YET RECRUITING
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
Zhejiang University
NCT06906562 RECRUITING
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Sameek Roychowdhury
NCT07240766 RECRUITING
HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
Zhejiang University
NCT06384560 RECRUITING
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Amsterdam UMC, location VUmc
NCT05466799 ACTIVE NOT RECRUITING
FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
OncoSil Medical Limited
NCT05558982 ACTIVE NOT RECRUITING
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Georgetown University
NCT06219941 RECRUITING
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
NCT04115163 RECRUITING
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Anne Noonan
NCT05908747 ACTIVE NOT RECRUITING
Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT03851614 ACTIVE NOT RECRUITING
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
University Health Network, Toronto
NCT06662006 RECRUITING
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT07386704 ENROLLING BY INVITATION
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
Peking University First Hospital
NCT06381154 RECRUITING
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
NCT07377526 NOT YET RECRUITING
Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer
M.D. Anderson Cancer Center
NCT07148128 RECRUITING
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Auricula Biosciences Inc.
NCT06951997 RECRUITING
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT07312422 RECRUITING
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Zhejiang Provincial People's Hospital
NCT04098237 ACTIVE NOT RECRUITING
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
Andrew Hendifar, MD
NCT06428409 RECRUITING
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Merck Sharp & Dohme LLC
NCT02584244 RECRUITING
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Lumicell, Inc.
NCT06168812 ACTIVE NOT RECRUITING
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT07342725 NOT YET RECRUITING
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Ruijin Hospital
NCT05688215 RECRUITING
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Jonsson Comprehensive Cancer Center
NCT07344220 ENROLLING BY INVITATION
Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate
Hoag Memorial Hospital Presbyterian
NCT04539808 ACTIVE NOT RECRUITING
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
NCT07296341 RECRUITING
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06334432 ACTIVE NOT RECRUITING
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
NCT03977233 RECRUITING
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT05651022 ACTIVE NOT RECRUITING
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc
NCT03104439 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
Massachusetts General Hospital
NCT07333287 NOT YET RECRUITING
A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.
Shandong Provincial Hospital
NCT03322995 RECRUITING
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
Medical College of Wisconsin
NCT06399757 RECRUITING
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics Ltd
NCT04241276 ACTIVE NOT RECRUITING
A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer
Queen Mary University of London
NCT06547736 RECRUITING
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
Fudan University
NCT07131514 RECRUITING
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Ruijin Hospital
NCT07110064 RECRUITING
QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer
Du Juan
NCT07235202 RECRUITING
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
Shenzhen Majory Biotechnology Co., Ltd.
NCT07306286 RECRUITING
Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
Ruijin Hospital
NCT07306273 RECRUITING
IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
Ruijin Hospital
NCT06861452 RECRUITING
Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma
EIR Biotherapies s.r.l.
NCT04146298 RECRUITING
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Changhai Hospital
NCT03991962 ACTIVE NOT RECRUITING
Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
Yale University
NCT07301229 NOT YET RECRUITING
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer
Shanghai Henlius Biotech
NCT07303465 RECRUITING
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Ranok Therapeutics (Hangzhou) Co., Ltd.
NCT07226856 RECRUITING
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Mayo Clinic
NCT05249101 ACTIVE NOT RECRUITING
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
CG Pharmaceuticals, Inc
NCT04396821 ACTIVE NOT RECRUITING
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT02955940 ACTIVE NOT RECRUITING
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
NCT07284277 RECRUITING
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
Clinica Universidad de Navarra, Universidad de Navarra
NCT04858009 RECRUITING
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Mayo Clinic
NCT04390399 ACTIVE NOT RECRUITING
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ImmunityBio, Inc.
NCT07280377 ACTIVE NOT RECRUITING
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Oncolytics Biotech
NCT03556228 RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
NCT07277452 NOT YET RECRUITING
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
NCT06943521 RECRUITING
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
NCT02481635 ACTIVE NOT RECRUITING
A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
University Health Network, Toronto
NCT04570943 RECRUITING
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
NCT04753879 RECRUITING
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02451982 ACTIVE NOT RECRUITING
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06782932 RECRUITING
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06333314 RECRUITING
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
UNICANCER
NCT03608631 RECRUITING
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
M.D. Anderson Cancer Center
NCT07233850 NOT YET RECRUITING
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
Shenyang Sunshine Pharmaceutical Co., LTD.
NCT06177522 NOT YET RECRUITING
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
Jinling Hospital, China
NCT05438459 RECRUITING
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
Kyushu University
NCT07230301 NOT YET RECRUITING
Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions
Sizhen Wang
NCT06773130 RECRUITING
HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
West China Hospital
NCT05630183 ACTIVE NOT RECRUITING
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Agenus Inc.
NCT05360732 ACTIVE NOT RECRUITING
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
Fox Chase Cancer Center
NCT05379985 RECRUITING
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
NCT04926467 RECRUITING
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Baylor Research Institute
NCT06576115 RECRUITING
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
NCT05482893 RECRUITING
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
NCT04821284 ACTIVE NOT RECRUITING
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
Flemming Forsberg
NCT03080974 RECRUITING
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
University of Louisville
NCT05706129 RECRUITING
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
ITM Oncologics GmbH
NCT04888312 ACTIVE NOT RECRUITING
Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
Alligator Bioscience AB
NCT03245541 ACTIVE NOT RECRUITING
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT07208539 NOT YET RECRUITING
AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
Shanghai Zhongshan Hospital
NCT03915678 RECRUITING
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Institut Bergonié
NCT03492671 RECRUITING
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
Loma Linda University
NCT05518903 RECRUITING
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
Mayo Clinic
NCT03563248 ACTIVE NOT RECRUITING
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
NCT07096362 RECRUITING
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
University of Miami
NCT05093231 RECRUITING
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Cambridge University Hospitals NHS Foundation Trust
NCT06747845 RECRUITING
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
Abramson Cancer Center at Penn Medicine
NCT07175389 NOT YET RECRUITING
JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
West China Hospital
NCT07173387 ACTIVE NOT RECRUITING
Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer
Shandong Cancer Hospital and Institute
NCT07172802 RECRUITING
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
GI Innovation, Inc.
NCT06831136 RECRUITING
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
The University of Texas Health Science Center, Houston
NCT02598349 RECRUITING
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Proton Collaborative Group
NCT06313970 RECRUITING
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Fudan University
NCT05585320 ACTIVE NOT RECRUITING
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
NCT05451849 ACTIVE NOT RECRUITING
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT01088789 ACTIVE NOT RECRUITING
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06587061 RECRUITING
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Ruijin Hospital
NCT04111172 ACTIVE NOT RECRUITING
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
Thomas Jefferson University
NCT06758544 RECRUITING
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
Guangdong Provincial People's Hospital
NCT05864144 ACTIVE NOT RECRUITING
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
NCT04669197 ACTIVE NOT RECRUITING
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
HonorHealth Research Institute
NCT06843551 RECRUITING
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Benjamin Spieler
NCT06298916 RECRUITING
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Lantheus Medical Imaging
NCT05057013 ACTIVE NOT RECRUITING
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
NCT06196671 NOT YET RECRUITING
Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
Fudan University
NCT06149689 RECRUITING
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer
Fudan University
NCT07108504 NOT YET RECRUITING
Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Shanghai Zhongshan Hospital
NCT07101679 RECRUITING
A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer
West China Hospital
NCT06249321 RECRUITING
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
Fudan University
NCT07097064 NOT YET RECRUITING
Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers
Institut du Cancer de Montpellier - Val d'Aurelle
NCT06105021 ACTIVE NOT RECRUITING
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Affini-T Therapeutics, Inc.
NCT05969171 RECRUITING
A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Fudan University
NCT06605430 RECRUITING
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
HealthPartners Institute
NCT06015724 RECRUITING
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Georgetown University
NCT03806309 ACTIVE NOT RECRUITING
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT04348045 ACTIVE NOT RECRUITING
Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT05604560 ACTIVE NOT RECRUITING
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Lei Zheng
NCT06266143 ACTIVE NOT RECRUITING
A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer
Wuhan YZY Biopharma Co., Ltd.
NCT06024824 RECRUITING
Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)
Cancer Trials Ireland
NCT05132504 RECRUITING
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Baylor College of Medicine
NCT07066995 RECRUITING
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
Essen Biotech
NCT03935893 RECRUITING
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT04098081 ACTIVE NOT RECRUITING
1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
University of Maryland, Baltimore
NCT07028424 NOT YET RECRUITING
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT06825546 RECRUITING
Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
Sir Run Run Shaw Hospital
NCT03175224 RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics Inc.
NCT04901741 NOT YET RECRUITING
Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer
TME Pharma AG
NCT07040228 RECRUITING
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
Junjie Hang
NCT05451043 RECRUITING
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
NCT06435260 RECRUITING
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Hebei Medical University Fourth Hospital
NCT04543071 RECRUITING
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Gulam Manji
NCT06135896 RECRUITING
Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
National Cancer Center, Korea
NCT02843945 RECRUITING
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
CivaTech Oncology
NCT03856658 ACTIVE NOT RECRUITING
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
Corewell Health West
NCT05929885 RECRUITING
Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients
National Cancer Centre, Singapore
NCT04581473 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
CARsgen Therapeutics Co., Ltd.
NCT05851924 RECRUITING
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Memorial Sloan Kettering Cancer Center
NCT05141149 RECRUITING
First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer
Prestige Biopharma Limited
NCT06199895 RECRUITING
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
Liu Huang
NCT06944106 RECRUITING
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT04084496 RECRUITING
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Sun Yat-sen University
NCT02340117 ACTIVE NOT RECRUITING
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
SynerGene Therapeutics, Inc.
NCT06991491 NOT YET RECRUITING
Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)
West China Hospital
NCT03073785 ACTIVE NOT RECRUITING
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
University of Nebraska
NCT05827055 ACTIVE NOT RECRUITING
Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
Georgetown University
NCT05102721 ACTIVE NOT RECRUITING
Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
Vaccinex Inc.
NCT04990609 RECRUITING
EUS-RFA PANCARDINAL-1 Trial
The University of Texas Health Science Center, Houston
NCT06962267 RECRUITING
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT02983578 ACTIVE NOT RECRUITING
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
NCT04503265 RECRUITING
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AtlasMedx, Incorporated
NCT05827796 RECRUITING
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
InxMed (Shanghai) Co., Ltd.
NCT02912949 ACTIVE NOT RECRUITING
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Partner Therapeutics, Inc.
NCT06946901 RECRUITING
The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial
Shanghai Zhongshan Hospital
NCT05736731 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT06938282 NOT YET RECRUITING
An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
Shanghai Zhongshan Hospital
NCT06938503 NOT YET RECRUITING
AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT05915351 ACTIVE NOT RECRUITING
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
University of Kansas Medical Center
NCT06916975 NOT YET RECRUITING
Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Jin Xu
NCT05776524 RECRUITING
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
THERABIONIC INC.
NCT06888674 NOT YET RECRUITING
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
Zhejiang University
NCT06888648 NOT YET RECRUITING
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
Zhejiang University
NCT04802876 ACTIVE NOT RECRUITING
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
SOLTI Breast Cancer Research Group
NCT01585805 ACTIVE NOT RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT03579836 RECRUITING
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
BeyondBio Inc.
NCT06866977 NOT YET RECRUITING
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
Xiangya Hospital of Central South University
NCT04825288 ACTIVE NOT RECRUITING
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
XBiotech, Inc.
NCT04381130 NOT YET RECRUITING
A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer
Everfront Biotech Co., Ltd.
NCT05927142 RECRUITING
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
Joachim Aerts, MD PhD
NCT06816914 RECRUITING
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial
Taichung Veterans General Hospital
NCT06819215 RECRUITING
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
NCT06750861 NOT YET RECRUITING
QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06792435 RECRUITING
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Evopoint Biosciences Inc.
NCT06736717 RECRUITING
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
University of Kansas Medical Center
NCT05472259 RECRUITING
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
Belgian Group of Digestive Oncology
NCT05355298 ACTIVE NOT RECRUITING
ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Amplia Therapeutics Limited
NCT05431270 RECRUITING
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
NCT06789679 RECRUITING
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT04986930 ACTIVE NOT RECRUITING
mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Asan Medical Center
NCT05562297 NOT YET RECRUITING
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
Shanghai Zhongshan Hospital
NCT06782555 RECRUITING
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
ImmunoGenesis
NCT06782685 RECRUITING
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
Dai, Guanghai
NCT06766019 ACTIVE NOT RECRUITING
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
NCT04404595 ACTIVE NOT RECRUITING
Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
CARsgen Therapeutics Co., Ltd.
NCT06761027 RECRUITING
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
Fujian Provincial Hospital
NCT03368963 ACTIVE NOT RECRUITING
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
NCT05218889 RECRUITING
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
NCT04827953 ACTIVE NOT RECRUITING
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
Nelum Corp
NCT06405490 RECRUITING
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05859750 RECRUITING
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Akeso
NCT06722911 RECRUITING
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
Zhejiang Provincial People's Hospital
NCT06472037 RECRUITING
AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC
Tianjin Medical University Cancer Institute and Hospital
NCT06700603 NOT YET RECRUITING
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
Rui-hua Xu, MD, PhD
NCT06690528 RECRUITING
Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver
Azienda Ospedaliera di Padova
NCT06598007 RECRUITING
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Crossignal Therapeutics, Inc.
NCT06669078 NOT YET RECRUITING
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT06389760 RECRUITING
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT06662669 NOT YET RECRUITING
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.
NCT05659914 ACTIVE NOT RECRUITING
Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
NCT05462496 RECRUITING
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
NCT05620134 ACTIVE NOT RECRUITING
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
NCT04452461 RECRUITING
Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery
Hamilton Health Sciences Corporation
NCT04913337 ACTIVE NOT RECRUITING
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
NCT06621095 NOT YET RECRUITING
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
RenJi Hospital
NCT04205227 ACTIVE NOT RECRUITING
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
ENB Therapeutics, Inc
NCT03269526 ACTIVE NOT RECRUITING
BATs Treatment for Pancreatic Cancer, Phase Ib/II
University of Virginia
NCT06261359 RECRUITING
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
Qilu Pharmaceutical Co., Ltd.
NCT06224387 RECRUITING
CTS2190 Phase I /II Clinical Study in Patients
CytosinLab Therapeutics Co., Ltd.
NCT06475326 RECRUITING
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
Fudan University
NCT06427239 RECRUITING
Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer
Fudan University
NCT06531278 RECRUITING
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
Jiang Long
NCT06513455 NOT YET RECRUITING
Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer
Harbin Medical University
NCT06387810 RECRUITING
Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer
Peking Union Medical College Hospital
NCT06491472 RECRUITING
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT06454448 RECRUITING
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT06359275 RECRUITING
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Fudan University
NCT06467565 RECRUITING
NALIRIFOX as Induction Therapy in LAPC
The First Affiliated Hospital with Nanjing Medical University
NCT05766748 RECRUITING
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
Cantex Pharmaceuticals
NCT06018896 RECRUITING
Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
Fudan University
NCT06436976 RECRUITING
The Effect of Probiotics ATG-F4 in Cancer Patients
Chungnam National University Hospital
NCT06429904 ACTIVE NOT RECRUITING
Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer
Peking Union Medical College Hospital
NCT06427460 RECRUITING
Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)
Changhai Hospital
NCT06422156 NOT YET RECRUITING
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
Peking University Third Hospital
NCT03337087 ACTIVE NOT RECRUITING
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
NCT04672005 ACTIVE NOT RECRUITING
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
Lyudmyla Berim
NCT06404840 RECRUITING
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
Tianjin Medical University Cancer Institute and Hospital
NCT03351296 ACTIVE NOT RECRUITING
Two Chemotherapy Regimens Plus or Minus Bevacizumab
Gustave Roussy, Cancer Campus, Grand Paris
NCT06329947 NOT YET RECRUITING
A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
Rui-hua Xu, MD, PhD
NCT06078787 RECRUITING
Olaparib in PALB2 Advanced Pancreatic Cancer
Azienda Ospedaliero-Universitaria di Modena
NCT06370754 NOT YET RECRUITING
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
Fudan University
NCT06361030 NOT YET RECRUITING
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT06111274 RECRUITING
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
Abbisko Therapeutics Co, Ltd
NCT06345599 NOT YET RECRUITING
PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)
Second Affiliated Hospital of Soochow University
NCT06145074 RECRUITING
Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.
Zealand University Hospital
NCT06196788 RECRUITING
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
Fudan University
NCT06259058 NOT YET RECRUITING
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT06233877 NOT YET RECRUITING
Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer
Hirschfeld Oncology
NCT06151262 RECRUITING
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT05988814 RECRUITING
Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy
Centre Georges Francois Leclerc
NCT06245330 RECRUITING
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
Ascentawits Pharmaceuticals, Ltd
NCT06234072 NOT YET RECRUITING
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
Shenzhen University General Hospital
NCT06210360 NOT YET RECRUITING
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
Changhai Hospital
NCT06060405 RECRUITING
Durvalumab and Oleclumab in Resectable PDAC
University Health Network, Toronto
NCT02446093 ACTIVE NOT RECRUITING
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Candel Therapeutics, Inc.
NCT06172036 NOT YET RECRUITING
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
Zhejiang University
NCT06159478 RECRUITING
Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
National Cancer Center, Japan
NCT06166589 NOT YET RECRUITING
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
Shanghai Zhongshan Hospital
NCT05810792 NOT YET RECRUITING
Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer
Sahlgrenska University Hospital
NCT05637567 NOT YET RECRUITING
Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head
German Cancer Research Center
NCT05988372 NOT YET RECRUITING
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
Sun Yat-sen University
NCT06051851 RECRUITING
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT06009029 NOT YET RECRUITING
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
Peking University Third Hospital
NCT05083247 RECRUITING
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Erasme University Hospital
NCT05733000 RECRUITING
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
NCT05679583 RECRUITING
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
Yonsei University
NCT04361162 ACTIVE NOT RECRUITING
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
Massachusetts General Hospital
NCT03498326 RECRUITING
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07600268 RECRUITING
Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer
Shandong Cancer Hospital and Institute
NCT07595835 RECRUITING
CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer
M.R. Meijerink
NCT07594626 NOT YET RECRUITING
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
Northwestern University
NCT07595172 RECRUITING
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
West China Hospital
NCT07589569 NOT YET RECRUITING
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
Shandong Suncadia Medicine Co., Ltd.
NCT07586813 RECRUITING
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Peking University People's Hospital
NCT06119217 COMPLETED
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
NCT03415854 COMPLETED
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
HonorHealth Research Institute
NCT03767582 COMPLETED
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05415917 WITHDRAWN
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Rutgers, The State University of New Jersey
NCT03797326 COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Merck Sharp & Dohme LLC
NCT04481204 WITHDRAWN
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
NCT06390059 COMPLETED
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
NovoCure Ltd.
NCT06630325 TERMINATED
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
NCT05014776 COMPLETED
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03915444 COMPLETED
Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
HonorHealth Research Institute
NCT03138720 COMPLETED
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
HonorHealth Research Institute
NCT04387071 TERMINATED
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
University of Southern California
NCT05518110 TERMINATED
PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
Cancer Trials Ireland
NCT02985125 COMPLETED
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
Georgetown University
NCT02077881 COMPLETED
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
NewLink Genetics Corporation
NCT05586516 COMPLETED
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
NCT05039177 COMPLETED
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Erasca, Inc.
NCT06538623 COMPLETED
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
NCT03745326 TERMINATED
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT02648282 COMPLETED
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01204372 COMPLETED
Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
Institut du Cancer de Montpellier - Val d'Aurelle
NCT04332653 COMPLETED
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NCT02047474 COMPLETED
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
NCT02890355 COMPLETED
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT04975516 TERMINATED
Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
Mayo Clinic
NCT04426669 COMPLETED
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
NCT03785210 TERMINATED
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Cancer Institute (NCI)
NCT04469556 COMPLETED
Pancreatic Adenocarcinoma Signature Stratification for Treatment
University Health Network, Toronto
NCT05000294 SUSPENDED
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
NCT05442749 TERMINATED
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
Centre Leon Berard
NCT03983057 COMPLETED
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
Zhejiang University
NCT03727880 COMPLETED
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
Lei Zheng
NCT04524702 COMPLETED
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
NCT05070247 TERMINATED
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
NCT06478862 TERMINATED
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
Lipomedix Pharmaceuticals Inc.
NCT04643405 TERMINATED
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Ascentage Pharma Group Inc.
NCT03443492 COMPLETED
SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer
National Health Research Institutes, Taiwan
NCT04752696 COMPLETED
Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
Cardiff Oncology
NCT03910387 COMPLETED
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Emory University
NCT05289830 TERMINATED
Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
Case Comprehensive Cancer Center
NCT05114213 TERMINATED
MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC
Ludwig-Maximilians - University of Munich
NCT04779151 TERMINATED
Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Gustave Roussy, Cancer Campus, Grand Paris
NCT05795595 COMPLETED
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics AG
NCT03193190 COMPLETED
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
NCT04054362 COMPLETED
Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Barts & The London NHS Trust
NCT07026916 WITHDRAWN
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
NCT05525286 TERMINATED
Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma
SOTIO Biotech a.s.
NCT04504916 TERMINATED
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT05194735 TERMINATED
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
NCT01489865 COMPLETED
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Georgetown University
NCT06069778 TERMINATED
Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
BioNTech SE
NCT05169437 TERMINATED
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Tempus AI
NCT03192462 COMPLETED
TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
Baylor College of Medicine
NCT04390763 TERMINATED
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Novartis Pharmaceuticals
NCT05494697 SUSPENDED
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
AIM ImmunoTech Inc.
NCT03404960 COMPLETED
Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy
University of Pennsylvania
NCT03184870 COMPLETED
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04257448 COMPLETED
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
GWT-TUD GmbH
NCT06690281 WITHDRAWN
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Cancer Institute (NCI)
NCT00964171 COMPLETED
Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Institut Bergonié
NCT02754726 COMPLETED
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
HonorHealth Research Institute
NCT04191421 COMPLETED
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Emory University
NCT05259696 COMPLETED
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Palleon Pharmaceuticals, Inc.
NCT04409002 COMPLETED
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
NCT04493060 COMPLETED
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
NCT03697564 COMPLETED
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
Hitendra Patel
NCT03033225 COMPLETED
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
Mayo Clinic
NCT04116073 COMPLETED
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03496662 COMPLETED
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Washington University School of Medicine
NCT01781728 COMPLETED
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01342354 COMPLETED
Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer
University of Chicago
NCT05239182 TERMINATED
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
Anwaar Saeed
NCT04992507 TERMINATED
Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study
Ohio State University Comprehensive Cancer Center
NCT05563272 TERMINATED
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Telix Pharmaceuticals (Innovations) Pty Ltd
NCT02611024 COMPLETED
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
NCT02723331 COMPLETED
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Academic Thoracic Oncology Medical Investigators Consortium
NCT03693677 COMPLETED
First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
Federation Francophone de Cancerologie Digestive
NCT06592664 WITHDRAWN
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
Lisata Therapeutics, Inc.
NCT05546476 COMPLETED
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Pfizer
NCT04068896 COMPLETED
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
NCT03250273 COMPLETED
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06241352 COMPLETED
Statin Addition to Chemotherapy for Advanced Pancreatic Cancer
Changhai Hospital
NCT01144455 COMPLETED
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
ImmunoGenesis
NCT01834235 TERMINATED
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Precision Biologics, Inc
NCT05251233 TERMINATED
Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Washington University School of Medicine
NCT01555489 TERMINATED
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Thomas Jefferson University
NCT02632448 COMPLETED
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
NCT00640978 TERMINATED
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
NCT03374852 WITHDRAWN
CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03610490 TERMINATED
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
NCT05673811 COMPLETED
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
Theriva Biologics SL
NCT04383210 TERMINATED
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
NCT03829501 TERMINATED
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
NCT02650804 COMPLETED
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
BPGbio
NCT06111872 COMPLETED
Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.
National University of Malaysia
NCT05360264 TERMINATED
tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr
Luca Cardone
NCT02879318 COMPLETED
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Canadian Cancer Trials Group
NCT04976660 WITHDRAWN
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
Tarus Therapeutics, Inc.
NCT01601808 COMPLETED
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
University of Liverpool
NCT04247165 COMPLETED
Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.
Herlev Hospital
NCT03058289 COMPLETED
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Intensity Therapeutics, Inc.
NCT02907099 COMPLETED
Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
NCT03822936 TERMINATED
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
CNAO National Center of Oncological Hadrontherapy
NCT04666688 COMPLETED
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
NCT03161379 COMPLETED
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04662112 COMPLETED
Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma
Asan Medical Center
NCT03699319 COMPLETED
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
David Bajor, MD
NCT05031494 COMPLETED
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Eucure (Beijing) Biopharma Co., Ltd
NCT02581215 COMPLETED
Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
Walid Shaib, MD
NCT05861336 WITHDRAWN
GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT03974854 TERMINATED
Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma
Centre Hospitalier Universitaire de Besancon
NCT04731467 COMPLETED
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Famewave Ltd.
NCT03997968 COMPLETED
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
NCT03329248 TERMINATED
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
NCT01905150 COMPLETED
Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
Bruckner Oncology
NCT03225989 COMPLETED
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
Lokon Pharma AB
NCT01064622 COMPLETED
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT03592264 TERMINATED
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
OBI Pharma, Inc
NCT03207867 TERMINATED
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis Pharmaceuticals
NCT03006302 COMPLETED
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04536077 TERMINATED
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Washington University School of Medicine
NCT04683939 TERMINATED
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
NCT02677038 COMPLETED
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
M.D. Anderson Cancer Center
NCT04098432 COMPLETED
STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma
University Hospital Hradec Kralove
NCT04156087 COMPLETED
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer
Baki Topal
NCT02745197 WITHDRAWN
A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer
University of Alberta
NCT05052567 COMPLETED
CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
Qilu Pharmaceutical Co., Ltd.
NCT02826486 COMPLETED
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
BioLineRx, Ltd.
NCT02431676 COMPLETED
Survivorship Promotion In Reducing IGF-1 Trial
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03486327 TERMINATED
Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
Bracco Diagnostics, Inc
NCT03267316 COMPLETED
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
Cantargia AB
NCT00819169 TERMINATED
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
NantCell, Inc.
NCT04228601 COMPLETED
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.
NCT06518538 WITHDRAWN
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
NCT01595321 COMPLETED
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03190265 COMPLETED
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03127098 TERMINATED
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
NCT02697058 COMPLETED
Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer
Institut de Recherches Internationales Servier
NCT03336216 COMPLETED
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Bristol-Myers Squibb
NCT06398587 WITHDRAWN
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
NCT02352337 COMPLETED
First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
Federation Francophone de Cancerologie Digestive
NCT02827201 COMPLETED
FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine
Federation Francophone de Cancerologie Digestive
NCT03077685 COMPLETED
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
NanOlogy, LLC
NCT03136406 TERMINATED
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
NCT01580397 COMPLETED
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
ImmunityBio, Inc.
NCT05116917 TERMINATED
Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
Herlev Hospital
NCT03450018 TERMINATED
A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX
British Columbia Cancer Agency
NCT03387098 TERMINATED
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
NCT04698915 TERMINATED
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
Galera Therapeutics, Inc.
NCT04390243 TERMINATED
Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
Academic and Community Cancer Research United
NCT03146962 COMPLETED
High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
Weill Medical College of Cornell University
NCT04808362 TERMINATED
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
Peptomyc S.L.
NCT03848182 TERMINATED
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
Albert Einstein College of Medicine
NCT03127124 WITHDRAWN
QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer
NantPharma, LLC
NCT04431258 COMPLETED
ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
Ability Pharmaceuticals SL
NCT04617067 COMPLETED
Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
Cancer Trials Ireland
NCT02128100 COMPLETED
Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
University of Louisville
NCT06278493 COMPLETED
A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04177810 COMPLETED
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01959139 COMPLETED
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
SWOG Cancer Research Network
NCT01525082 COMPLETED
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Shaheen Shagufta
NCT03376659 TERMINATED
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Georgetown University
NCT04624217 COMPLETED
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.
NCT03340974 COMPLETED
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
Galera Therapeutics, Inc.
NCT03189914 COMPLETED
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
Processa Pharmaceuticals
NCT01897454 TERMINATED
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
NCT04637698 TERMINATED
OH2 Oncolytic Viral Therapy in Pancreatic Cancer
Binhui Biopharmaceutical Co., Ltd.
NCT04565327 TERMINATED
Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma
Zhen Wang, MD
NCT02178436 COMPLETED
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
Mohammed Najeeb Al Hallak
NCT00625586 TERMINATED
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
MacroGenics
NCT04983407 TERMINATED
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
Aravive, Inc.
NCT02383433 TERMINATED
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Case Comprehensive Cancer Center
NCT03714555 TERMINATED
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
HonorHealth Research Institute
NCT03117920 COMPLETED
A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer
Minneamrita Therapeutics LLC
NCT01959672 COMPLETED
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
University of Nebraska
NCT02504333 COMPLETED
Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
NCT05906615 COMPLETED
Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT03140670 TERMINATED
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
Abramson Cancer Center at Penn Medicine
NCT02866383 COMPLETED
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
Herlev Hospital
NCT03953235 COMPLETED
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
Gritstone bio, Inc.
NCT02427841 COMPLETED
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
OHSU Knight Cancer Institute
NCT01470417 COMPLETED
Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
University of Florida
NCT04953962 COMPLETED
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
CanBas Co. Ltd.
NCT01726582 COMPLETED
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
NCT03602079 COMPLETED
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
NCT05926206 WITHDRAWN
Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas
University of Michigan Rogel Cancer Center
NCT03576131 TERMINATED
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Genmab
NCT02324543 COMPLETED
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00965718 COMPLETED
Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer
GC Cell Corporation
NCT04212026 TERMINATED
Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.
University Hospital, Basel, Switzerland
NCT02775695 COMPLETED
Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer
Medical College of Wisconsin
NCT02047513 COMPLETED
Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
AIO-Studien-gGmbH
NCT02042378 COMPLETED
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
pharmaand GmbH
NCT03745430 COMPLETED
RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Hellenic Cooperative Oncology Group
NCT02620865 COMPLETED
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
NCT01845337 COMPLETED
Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
University of Edinburgh
NCT05251038 WITHDRAWN
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Devalingam Mahalingam
NCT02578732 COMPLETED
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Brown University
NCT02194829 COMPLETED
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03410030 COMPLETED
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
HonorHealth Research Institute
NCT02806687 COMPLETED
Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer
University Hospital, Toulouse
NCT03717298 COMPLETED
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
Catalysis SL
NCT03801915 COMPLETED
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
National Cancer Institute (NCI)
NCT02707159 COMPLETED
Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients
Helse Stavanger HF
NCT02210559 COMPLETED
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Kyntra Bio
NCT02028806 COMPLETED
mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer
Yuhong Li
NCT02426281 COMPLETED
Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Samsung Medical Center
NCT04224402 COMPLETED
Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.
Yuhong Li
NCT01647828 COMPLETED
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
OncoMed Pharmaceuticals, Inc.
NCT03977272 COMPLETED
Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer
Zhejiang University
NCT02713529 COMPLETED
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
AmMax Bio, Inc.
NCT03331562 COMPLETED
A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
Translational Genomics Research Institute
NCT03214250 COMPLETED
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Parker Institute for Cancer Immunotherapy
NCT01939665 COMPLETED
PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma
Amsterdam UMC, location VUmc
NCT02564146 COMPLETED
First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine
AIO-Studien-gGmbH
NCT03318497 COMPLETED
Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma
University of Texas Southwestern Medical Center
NCT02428270 COMPLETED
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
University Health Network, Toronto
NCT03099265 TERMINATED
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Yale University
NCT02562716 COMPLETED
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
SWOG Cancer Research Network
NCT02551991 COMPLETED
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Ipsen
NCT03723915 TERMINATED
Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer
Northwestern University
NCT01845805 COMPLETED
Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03158779 COMPLETED
Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer
Istituto Clinico Humanitas
NCT01547260 COMPLETED
Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer
Maria Liljefors
NCT02080221 COMPLETED
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Brown University
NCT03559348 COMPLETED
Locally Advanced or Metastatic Pancreatic Adenocarcinoma
National Health Research Institutes, Taiwan
NCT03086369 COMPLETED
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
NCT01461915 TERMINATED
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
Jazz Pharmaceuticals
NCT02022033 COMPLETED
BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Brown University
NCT04327986 TERMINATED
Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
National Cancer Institute (NCI)
NCT02704156 COMPLETED
SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer
Changhai Hospital
NCT02850874 WITHDRAWN
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
Wake Forest University Health Sciences
NCT02080260 COMPLETED
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
Wake Forest University Health Sciences
NCT04258150 TERMINATED
Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
Herlev Hospital
NCT01360593 COMPLETED
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
David A. Clump, MD, PhD
NCT02131493 COMPLETED
S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer
Zhejiang University
NCT00617708 COMPLETED
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT03637491 TERMINATED
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
Pfizer
NCT04790695 COMPLETED
Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab
Ottawa Hospital Research Institute
NCT03331640 TERMINATED
A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy
AIO-Studien-gGmbH
NCT04105062 WITHDRAWN
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Washington University School of Medicine
NCT04070313 TERMINATED
A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
TTY Biopharm
NCT01303172 COMPLETED
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Immodulon Therapeutics Ltd
NCT01660711 COMPLETED
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Endeavor Health
NCT03023722 COMPLETED
Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
Yale University
NCT03599362 TERMINATED
Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
NYU Langone Health
NCT03261947 COMPLETED
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT00603863 COMPLETED
Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer
Gilead Sciences
NCT01631552 COMPLETED
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
NCT01666730 COMPLETED
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
Case Comprehensive Cancer Center
NCT03451773 TERMINATED
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
National Cancer Institute (NCI)
NCT01459614 COMPLETED
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01053013 COMPLETED
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
The Rogosin Institute
NCT04464967 WITHDRAWN
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
NCT02562898 COMPLETED
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Margaret Tempero
NCT01210911 COMPLETED
Metformin Combined With Chemotherapy for Pancreatic Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT01077986 COMPLETED
Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT02311361 COMPLETED
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
NCT02985801 TERMINATED
PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
Massimo Raimondo, M.D.
NCT01206296 TERMINATED
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
Medstar Health Research Institute
NCT01839799 COMPLETED
A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma
Abramson Cancer Center at Penn Medicine
NCT03040986 COMPLETED
Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
National Cancer Institute (NCI)
NCT02921737 TERMINATED
TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
University of Florida
NCT03415802 COMPLETED
Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
Aiping Zhou
NCT03585062 TERMINATED
Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer
Zhejiang Provincial People's Hospital
NCT01652976 COMPLETED
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
University of Florida
NCT01964287 COMPLETED
First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.
Institut du Cancer de Montpellier - Val d'Aurelle
NCT03979066 TERMINATED
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
Gulam Manji
NCT03042780 TERMINATED
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
NCT04262388 WITHDRAWN
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
University Health Network, Toronto
NCT01397019 COMPLETED
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Per Pfeiffer
NCT03180437 COMPLETED
Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
NCT02459652 COMPLETED
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
Japan Adjuvant Study Group of Pancreatic Cancer
NCT03509298 WITHDRAWN
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
NCT02289898 COMPLETED
Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
OncoMed Pharmaceuticals, Inc.
NCT03038477 WITHDRAWN
A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
University of Colorado, Denver
NCT00769483 COMPLETED
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
NCT03213626 TERMINATED
Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
Patrick Joseph Loehrer Sr.
NCT01560949 COMPLETED
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
M.D. Anderson Cancer Center
NCT03469258 TERMINATED
Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma
Dana-Farber Cancer Institute
NCT01222689 COMPLETED
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT00882765 WITHDRAWN
Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Jonsson Comprehensive Cancer Center
NCT01839487 COMPLETED
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Halozyme Therapeutics
NCT03168139 COMPLETED
Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer
TME Pharma AG
NCT02405585 TERMINATED
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
NewLink Genetics Corporation
NCT00614601 TERMINATED
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
NewLink Genetics Corporation
NCT01896869 COMPLETED
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02261714 COMPLETED
Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer
Targovax ASA
NCT03344172 TERMINATED
Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer
Nathan Bahary, MD
NCT02628860 COMPLETED
Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy
National Cancer Center, Korea
NCT04058964 WITHDRAWN
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
NCT00727441 COMPLETED
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01392352 TERMINATED
HYPAZ: Hypertension Induced by Pazopanib
Cambridge University Hospitals NHS Foundation Trust
NCT04134468 WITHDRAWN
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Abramson Cancer Center at Penn Medicine
NCT02743975 TERMINATED
Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma
University Medical Center Groningen
NCT01431794 TERMINATED
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02358161 COMPLETED
Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT02541370 COMPLETED
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Chinese PLA General Hospital
NCT03300843 TERMINATED
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
National Cancer Institute (NCI)
NCT01240304 TERMINATED
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
University of Arkansas
NCT00728000 WITHDRAWN
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
University of Cincinnati
NCT02749136 COMPLETED
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
Asan Medical Center
NCT02981342 COMPLETED
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Eli Lilly and Company
NCT03891472 COMPLETED
Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer
Medical University of Silesia
NCT01661088 COMPLETED
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
University of Michigan Rogel Cancer Center
NCT02106884 COMPLETED
Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel
Universitaire Ziekenhuizen KU Leuven
NCT00733746 COMPLETED
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
NCT04130399 WITHDRAWN
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Indiana University
NCT01583686 TERMINATED
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Cancer Institute (NCI)
NCT02043730 COMPLETED
Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
NCT01806675 COMPLETED
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Sanjiv Sam Gambhir
NCT02362048 COMPLETED
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
Acerta Pharma BV
NCT01524575 WITHDRAWN
Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
University of Hawaii
NCT01505530 COMPLETED
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Eli Lilly and Company
NCT02449967 WITHDRAWN
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
NCT01028495 COMPLETED
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals, Inc.
NCT03008304 COMPLETED
High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
NCT02718859 COMPLETED
Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
NCT02570711 TERMINATED
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
Acerta Pharma BV
NCT02352831 TERMINATED
Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Washington University School of Medicine
NCT02583477 COMPLETED
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
AstraZeneca
NCT01858883 COMPLETED
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Incyte Corporation
NCT02124369 TERMINATED
Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)
CCTU- Cancer Theme
NCT02736578 TERMINATED
Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
Eben Rosenthal
NCT01132755 COMPLETED
Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Memorial Sloan Kettering Cancer Center
NCT03697239 WITHDRAWN
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Hitendra Patel
NCT03797443 WITHDRAWN
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Piedmont Cancer Institute
NCT03432676 WITHDRAWN
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
NCT03908333 WITHDRAWN
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Medical College of Wisconsin
NCT01893801 COMPLETED
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Pancreatic Cancer Research Team
NCT03392571 WITHDRAWN
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
Pancreatic Cancer Research Team
NCT01128296 COMPLETED
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
Amer Zureikat
NCT01088815 COMPLETED
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00923299 COMPLETED
Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine
Institut du Cancer de Montpellier - Val d'Aurelle
NCT02910882 TERMINATED
PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
Scripps Health
NCT02950025 TERMINATED
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
Washington University School of Medicine
NCT00735917 COMPLETED
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT01978184 COMPLETED
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
Nathan Bahary, MD
NCT01760252 TERMINATED
Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol
Beth Israel Medical Center
NCT01233375 COMPLETED
Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma
Clovis Oncology, Inc.
NCT02440958 COMPLETED
Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial
Yonsei University
NCT02023021 COMPLETED
Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
Xian-Jun Yu
NCT02005419 COMPLETED
Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
Xian-Jun Yu
NCT02732938 TERMINATED
Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
Pfizer
NCT01632306 TERMINATED
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
NCT02403271 COMPLETED
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Pharmacyclics LLC.
NCT01453153 COMPLETED
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Halozyme Therapeutics
NCT02669914 TERMINATED
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Washington University School of Medicine
NCT01032057 COMPLETED
Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
Lisette Nixon
NCT02399137 COMPLETED
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Merrimack Pharmaceuticals
NCT02967770 WITHDRAWN
Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer
Georgetown University
NCT01621243 TERMINATED
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Momenta Pharmaceuticals, Inc.
NCT02558894 COMPLETED
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
AstraZeneca
NCT02195180 COMPLETED
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
ERYtech Pharma
NCT02241551 TERMINATED
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
Nathan Bahary, MD
NCT01921751 TERMINATED
High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Radiation Therapy Oncology Group
NCT02345460 TERMINATED
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Case Comprehensive Cancer Center
NCT02767752 TERMINATED
Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
Herlev Hospital
NCT02331251 TERMINATED
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
NCT02423954 TERMINATED
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Western Regional Medical Center
NCT02004262 COMPLETED
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Aduro Biotech, Inc.
NCT01389440 COMPLETED
Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer
Grupo Espanol Multidisciplinario del Cancer Digestivo
NCT01373164 COMPLETED
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
NCT00889187 TERMINATED
Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer
Dana-Farber Cancer Institute
NCT01417000 COMPLETED
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
Aduro Biotech, Inc.
NCT02638909 TERMINATED
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Criterium, Inc.
NCT01280058 COMPLETED
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT01851174 TERMINATED
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
Western Regional Medical Center
NCT01781520 COMPLETED
Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer
Capital Medical University
NCT00810719 COMPLETED
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
University of California, Davis
NCT01234935 COMPLETED
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Translational Oncology Research International
NCT01056601 TERMINATED
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota
NCT01146054 COMPLETED
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Stanford University
NCT00903396 TERMINATED
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
NCT01430052 COMPLETED
Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer
Osaka Medical Center for Cancer and Cardiovascular Diseases
NCT01688336 TERMINATED
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01553019 COMPLETED
Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer
University of Florida
NCT01150630 COMPLETED
Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer
IRCCS San Raffaele
NCT01730222 COMPLETED
A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma
IRCCS San Raffaele
NCT01531712 TERMINATED
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
Institut Català d'Oncologia
NCT01195415 COMPLETED
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
NCT01040000 COMPLETED
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Precision Biologics, Inc
NCT01303029 COMPLETED
Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
NCT02035072 COMPLETED
Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT00609336 COMPLETED
Perioperative Therapy for Resectable Pancreatic Cancer
University of Washington
NCT01016483 COMPLETED
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
EMD Serono
NCT02117258 COMPLETED
Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma
Zeria Pharmaceutical
NCT01273805 COMPLETED
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
NCT01515046 TERMINATED
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
Joseph J. Cullen
NCT00841035 TERMINATED
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
University of Alabama at Birmingham
NCT02243007 TERMINATED
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
Massachusetts General Hospital
NCT01844817 COMPLETED
Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
SCRI Development Innovations, LLC
NCT01608711 COMPLETED
A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
Agensys, Inc.
NCT02202785 TERMINATED
A Study of MLN0264 in Patients With Pancreatic Cancer
Millennium Pharmaceuticals, Inc.
NCT00691054 COMPLETED
Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
University of Miami
NCT00948688 TERMINATED
Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas
Massachusetts General Hospital
NCT01558869 COMPLETED
Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma
The University of Hong Kong
NCT01272791 COMPLETED
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
Peregrine Pharmaceuticals
NCT00601627 COMPLETED
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
Alliance for Clinical Trials in Oncology
NCT00550836 COMPLETED
Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
NCT00907166 TERMINATED
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Cornerstone Pharmaceuticals
NCT01175733 COMPLETED
Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer
Amsterdam UMC, location VUmc
NCT01130142 COMPLETED
A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
Infinity Pharmaceuticals, Inc.
NCT01895790 WITHDRAWN
Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer
Johns Hopkins University
NCT01108458 TERMINATED
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
George Albert Fisher
NCT01581307 COMPLETED
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
H. Lee Moffitt Cancer Center and Research Institute
NCT00944463 COMPLETED
Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients
Samsung Medical Center
NCT02109341 COMPLETED
Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer
Gruppo Oncologico Italiano di Ricerca Clinica
NCT03016637 COMPLETED
Pancreatic Core Biopsy Needle Study in Patients Suspected of Pancreatic Malignancy
Odense University Hospital
NCT02984501 COMPLETED
Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer
Campus Bio-Medico University
NCT01369420 COMPLETED
NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer
Angiodynamics, Inc.
NCT01661114 COMPLETED
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
University of Michigan Rogel Cancer Center
NCT01050426 TERMINATED
A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)
Royal Marsden NHS Foundation Trust
NCT00726037 TERMINATED
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
Loyola University
NCT01188109 TERMINATED
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Emory University
NCT01488552 COMPLETED
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Pancreatic Cancer Research Team
NCT01304160 COMPLETED
Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
NCT02382263 COMPLETED
Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer
PH Research, S.L.
NCT01473303 WITHDRAWN
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
NCT00674973 COMPLETED
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Hoffmann-La Roche
NCT00871169 COMPLETED
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
New Mexico Cancer Research Alliance
NCT01416662 COMPLETED
Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
Federation Francophone de Cancerologie Digestive
NCT00766636 TERMINATED
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
M.D. Anderson Cancer Center
NCT01415713 COMPLETED
The Study of Metastatic Pancreatic Adenocarcinoma
National Health Research Institutes, Taiwan
NCT01395017 COMPLETED
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT01658943 COMPLETED
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
National Cancer Institute (NCI)
NCT01693276 TERMINATED
Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
Olugbenga Olowokure
NCT01042028 TERMINATED
A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
Per Pfeiffer
NCT00633789 COMPLETED
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
Bristol-Myers Squibb
NCT00902291 COMPLETED
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Astellas Pharma Inc
NCT01754623 TERMINATED
GTX-RT in Borderline Resectable Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT00733850 COMPLETED
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
KangLaiTe USA
NCT01298011 COMPLETED
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
Pancreatic Cancer Research Team
NCT01080248 TERMINATED
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
Washington University School of Medicine
NCT00743379 COMPLETED
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Threshold Pharmaceuticals
NCT01167738 TERMINATED
Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer
IRCCS San Raffaele
NCT01587534 COMPLETED
Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)
National Cancer Center, Korea
NCT00998322 COMPLETED
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
NCT01130701 WITHDRAWN
A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .
University of Massachusetts, Worcester
NCT01472198 COMPLETED
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Gilead Sciences
NCT00652366 COMPLETED
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hoffmann-La Roche
NCT01628458 COMPLETED
Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer
UMC Utrecht
NCT00962312 COMPLETED
Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer
Cancer Trials Ireland
NCT01232829 COMPLETED
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
National Cancer Institute (NCI)
NCT01339754 COMPLETED
Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy
IRCCS San Raffaele
NCT00577889 COMPLETED
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
National Cancer Institute (NCI)
NCT01227018 TERMINATED
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
Vanderbilt-Ingram Cancer Center
NCT00837876 COMPLETED
Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Vanderbilt-Ingram Cancer Center
NCT01971034 COMPLETED
Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.
Instituto do Cancer do Estado de São Paulo
NCT01020006 COMPLETED
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Pharmacyclics LLC.
NCT01124786 COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
Clovis Oncology, Inc.
NCT01505413 COMPLETED
Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer
Soonchunhyang University Hospital
NCT00636883 TERMINATED
Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer
National Guard Health Affairs
NCT00910741 COMPLETED
NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia
NanoCarrier Co., Ltd.
NCT01096732 TERMINATED
Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)
Lisa Bax
NCT01830322 WITHDRAWN
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
NCT00837031 COMPLETED
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
SCRI Development Innovations, LLC
NCT00959946 TERMINATED
Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
Pfizer
NCT00922896 COMPLETED
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
Gyeongsang National University Hospital
NCT00709826 COMPLETED
APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
Tragara Pharmaceuticals, Inc.
NCT00862524 COMPLETED
A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer
Array BioPharma
NCT01186731 COMPLETED
Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
INSYS Therapeutics Inc
NCT01196247 COMPLETED
A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer
Translational Drug Development
NCT01320241 COMPLETED
Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture
Southeast University, China
NCT01543412 COMPLETED
Second Line Chemotherapy for Advanced Pancreatic Cancer
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
NCT00831493 TERMINATED
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
M.D. Anderson Cancer Center
NCT00967603 COMPLETED
Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer
IRCCS San Raffaele
NCT00898287 COMPLETED
Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer
Piramal Enterprises Limited
NCT00673504 COMPLETED
First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer
Central European Society for Anticancer Drug Research
NCT00683085 TERMINATED
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Tokyo University
NCT00810953 COMPLETED
A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy
Oncozyme Pharma Inc.
NCT00761241 COMPLETED
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
Benaroya Research Institute
NCT00637364 SUSPENDED
High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
CMED HIFU Development Corporation
NCT05005403 RECRUITING
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie
NCT07583771 NOT YET RECRUITING
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Chipscreen Biosciences, Ltd.
NCT06549751 NOT YET RECRUITING
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Marker Therapeutics, Inc.
NCT06673329 RECRUITING
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT03816358 ACTIVE NOT RECRUITING
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
National Cancer Institute (NCI)
NCT02595931 ACTIVE NOT RECRUITING
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT05877599 RECRUITING
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
NCT05411094 RECRUITING
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
NCT06465069 RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT04106856 ACTIVE NOT RECRUITING
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer (SHAPER)
University of Utah
NCT07458347 RECRUITING
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
NCT06141031 ACTIVE NOT RECRUITING
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
NCT04389632 RECRUITING
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04627246 ACTIVE NOT RECRUITING
Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer
Centre Hospitalier Universitaire Vaudois
NCT04104672 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
Arcus Biosciences, Inc.
NCT07300150 RECRUITING
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
PAQ Therapeutics, Inc.
NCT06835569 RECRUITING
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
NCT05365581 RECRUITING
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Global Development, Inc.
NCT07566897 NOT YET RECRUITING
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
Philogen S.p.A.
NCT05799274 RECRUITING
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Radiopharm Theranostics, Ltd
NCT07549958 RECRUITING
PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
University of California, Irvine
NCT06218914 RECRUITING
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
AstraZeneca
NCT07481383 RECRUITING
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
Continuity Biosciences, LLC
NCT07117032 NOT YET RECRUITING
Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain
Case Comprehensive Cancer Center
NCT06892054 RECRUITING
Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
NCT07021066 RECRUITING
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
SystImmune Inc.
NCT06648434 RECRUITING
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
NCT07488884 NOT YET RECRUITING
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
ImmunityBio, Inc.
NCT02495896 ACTIVE NOT RECRUITING
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
NCT07553793 NOT YET RECRUITING
Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients
Peking Union Medical College Hospital
NCT07261631 RECRUITING
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis Pharmaceuticals
NCT06147037 RECRUITING
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT05867121 ACTIVE NOT RECRUITING
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
NCT06562192 RECRUITING
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Novartis Pharmaceuticals
NCT04222413 RECRUITING
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT02600949 RECRUITING
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
M.D. Anderson Cancer Center
NCT00669734 ACTIVE NOT RECRUITING
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT06607185 ACTIVE NOT RECRUITING
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
NCT05208762 RECRUITING
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06131840 RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06586515 RECRUITING
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Eli Lilly and Company
NCT04158635 RECRUITING
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
City of Hope Medical Center
NCT05394259 RECRUITING
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
M.D. Anderson Cancer Center
NCT07094204 RECRUITING
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
NCT06026410 RECRUITING
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology, Inc.
NCT02381561 ACTIVE NOT RECRUITING
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
National Cancer Institute (NCI)
NCT06454383 RECRUITING
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
NCT01660971 ACTIVE NOT RECRUITING
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT00878163 ACTIVE NOT RECRUITING
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT06238479 ACTIVE NOT RECRUITING
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT05462717 ACTIVE NOT RECRUITING
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
NCT07090499 RECRUITING
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT06639724 RECRUITING
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
University of California, San Diego
NCT05846516 ACTIVE NOT RECRUITING
A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer
Boehringer Ingelheim
NCT05984602 ACTIVE NOT RECRUITING
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NYU Langone Health
NCT06917079 RECRUITING
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT05143970 RECRUITING
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Institut Paoli-Calmettes
NCT06585488 RECRUITING
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeiGene
NCT07454642 RECRUITING
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Avacta Life Sciences Ltd
NCT04678648 RECRUITING
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
NCT07481357 RECRUITING
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
Dong-A ST Co., Ltd.
NCT06882746 RECRUITING
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Boehringer Ingelheim
NCT07024615 RECRUITING
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Astellas Pharma Global Development, Inc.
NCT03875820 ACTIVE NOT RECRUITING
Phase I Trial of Defactinib and VS-6766.
Institute of Cancer Research, United Kingdom
NCT07189195 RECRUITING
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
University of California, Davis
NCT07227168 RECRUITING
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma, Inc.
NCT04900818 RECRUITING
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT07066657 RECRUITING
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
ArriVent BioPharma, Inc.
NCT06778863 RECRUITING
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics, Inc.
NCT05919238 RECRUITING
Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma
Impact Biotech Ltd
NCT06440005 RECRUITING
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex, Inc.
NCT05239143 ACTIVE NOT RECRUITING
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics, Inc.
NCT03740256 RECRUITING
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT06203821 NOT YET RECRUITING
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
Aram Hezel
NCT06217666 NOT YET RECRUITING
Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
Haoming (Carl) Qiu
NCT07349537 RECRUITING
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines, Inc.
NCT02336087 ACTIVE NOT RECRUITING
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
NCT07030283 RECRUITING
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
University of Colorado, Denver
NCT04150042 RECRUITING
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
General Oncology, Inc.
NCT07377045 RECRUITING
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
Oncomatryx Biopharma S.L.
NCT05827614 ACTIVE NOT RECRUITING
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Boundless Bio, Inc.
NCT06821048 RECRUITING
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
Weijia Fang, MD
NCT06084481 ACTIVE NOT RECRUITING
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
NCT07348107 NOT YET RECRUITING
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
Daniel Breadner
NCT06458712 RECRUITING
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Duke Street Bio Ltd
NCT06059001 ACTIVE NOT RECRUITING
Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC
Peptomyc S.L.
NCT06466187 ACTIVE NOT RECRUITING
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06076837 ACTIVE NOT RECRUITING
The Seven Trial: Exploiting the Unfolded Protein Response
HonorHealth Research Institute
NCT04673448 ACTIVE NOT RECRUITING
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
NCT06898385 RECRUITING
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
Sun Yat-sen University
NCT04161755 ACTIVE NOT RECRUITING
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Memorial Sloan Kettering Cancer Center
NCT06999187 RECRUITING
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT07314385 NOT YET RECRUITING
NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer
National Taiwan University Hospital
NCT06411691 RECRUITING
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05539430 ACTIVE NOT RECRUITING
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Legend Biotech USA Inc
NCT03257761 ACTIVE NOT RECRUITING
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
NCT05245500 RECRUITING
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
NCT05013216 RECRUITING
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04117087 ACTIVE NOT RECRUITING
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05723107 RECRUITING
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NYU Langone Health
NCT05034627 ACTIVE NOT RECRUITING
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
OHSU Knight Cancer Institute
NCT03983954 ACTIVE NOT RECRUITING
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NCT07106827 RECRUITING
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
NCT06981806 NOT YET RECRUITING
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma
Arsen Osipov
NCT02207465 ACTIVE NOT RECRUITING
A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
NCT06396091 ACTIVE NOT RECRUITING
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
Astellas Pharma Global Development, Inc.
NCT03889795 ACTIVE NOT RECRUITING
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
Danae Hamouda, MD
NCT05783622 RECRUITING
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
NCT04361708 RECRUITING
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
University of Chicago
NCT06896188 RECRUITING
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Anwaar Saeed
NCT04523987 ACTIVE NOT RECRUITING
A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
National University Hospital, Singapore
NCT05163028 ACTIVE NOT RECRUITING
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
HUYABIO International, LLC.
NCT06500052 RECRUITING
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06533332 RECRUITING
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
EtiraRx Australia Pty Ltd
NCT05227326 RECRUITING
AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
NCT05721846 ACTIVE NOT RECRUITING
Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer
Inna Chen, MD
NCT03854110 ACTIVE NOT RECRUITING
Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
Geistlich Pharma AG
NCT03454035 RECRUITING
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
NCT06789172 RECRUITING
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Epkin
NCT05209074 ACTIVE NOT RECRUITING
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Case Comprehensive Cancer Center
NCT05076760 RECRUITING
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen, Inc.
NCT06040541 RECRUITING
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
NCT06508307 RECRUITING
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
GONGCHU Biotechnology Co., Ltd
NCT06756035 RECRUITING
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
NCT06205849 RECRUITING
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
University of California, San Diego
NCT05141513 RECRUITING
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05055323 ACTIVE NOT RECRUITING
A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
Thomas Jefferson University
NCT05607953 ACTIVE NOT RECRUITING
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
TriSalus Life Sciences, Inc.
NCT05277766 RECRUITING
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
University Hospital, Ghent
NCT05057715 ACTIVE NOT RECRUITING
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
University of Pennsylvania
NCT07014878 NOT YET RECRUITING
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
Beijing DCTY Biotech Co.,Ltd.
NCT06596915 RECRUITING
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Shandong Boan Biotechnology Co., Ltd
NCT05740956 RECRUITING
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT04477343 RECRUITING
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
University of Rochester
NCT04157127 RECRUITING
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Diakonos Oncology Corporation
NCT06337084 RECRUITING
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Monopar Therapeutics
NCT04616534 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
National Cancer Institute (NCI)
NCT04137536 ACTIVE NOT RECRUITING
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT05919537 ACTIVE NOT RECRUITING
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Hummingbird Bioscience
NCT06532331 ACTIVE NOT RECRUITING
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
Ono Pharmaceutical Co., Ltd.
NCT05083780 ACTIVE NOT RECRUITING
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
Changhoon Yoo
NCT06278454 RECRUITING
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)
Chengdu New Radiomedicine Technology Co. LTD.
NCT04514497 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
NCT06344156 RECRUITING
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
Sichuan University
NCT03252808 ACTIVE NOT RECRUITING
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
Takara Bio Inc.
NCT06532344 ACTIVE NOT RECRUITING
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Ono Pharmaceutical Co., Ltd.
NCT05403554 RECRUITING
A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Light Chain Bioscience - Novimmune SA
NCT05215574 ACTIVE NOT RECRUITING
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NCT06614751 NOT YET RECRUITING
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
Danatlas Pharmaceuticals Co., Ltd
NCT06487377 RECRUITING
IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations
Shanghai Pudong Hospital
NCT05911217 RECRUITING
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
CARsgen Therapeutics Co., Ltd.
NCT06403735 RECRUITING
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06346808 NOT YET RECRUITING
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
Sichuan University
NCT06229496 RECRUITING
Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma
Chang Gung Memorial Hospital
NCT06134960 NOT YET RECRUITING
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
Peking University
NCT07594964 RECRUITING
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Shenzhen Xinhe Biomedical
NCT07589205 RECRUITING
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
NCT07587827 NOT YET RECRUITING
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
Centre Georges Francois Leclerc
NCT05685602 SUSPENDED
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
NCT03851237 COMPLETED
CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
Washington University School of Medicine
NCT06091930 COMPLETED
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
NCT03552718 COMPLETED
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
NCT05111353 COMPLETED
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Washington University School of Medicine
NCT05983133 TERMINATED
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT07173374 SUSPENDED
Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study
Shandong Cancer Hospital and Institute
NCT05085548 COMPLETED
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ProDa BioTech, LLC
NCT00885066 COMPLETED
Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Centre Antoine Lacassagne
NCT03403049 COMPLETED
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Montefiore Medical Center
NCT04132505 COMPLETED
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
NCT04484909 SUSPENDED
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
M.D. Anderson Cancer Center
NCT05411133 COMPLETED
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Arbele Pty Ltd
NCT06599502 TERMINATED
A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
AstraZeneca
NCT06287463 TERMINATED
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Deciphera Pharmaceuticals, LLC
NCT03065062 SUSPENDED
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
NCT06378047 COMPLETED
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05546853 COMPLETED
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
University Hospital, Grenoble
NCT06528093 TERMINATED
A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy
Boehringer Ingelheim
NCT05360680 COMPLETED
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cue Biopharma
NCT06626256 WITHDRAWN
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
NCT05977322 TERMINATED
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
Novartis Pharmaceuticals
NCT06199466 TERMINATED
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
NCT06129422 COMPLETED
Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
Nihon Medi-Physics Co., Ltd.
NCT02639026 COMPLETED
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
NCT05252390 TERMINATED
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
NCT04787991 COMPLETED
Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Cancer Insight, LLC
NCT04853017 COMPLETED
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Elicio Therapeutics
NCT05737615 WITHDRAWN
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Memorial Sloan Kettering Cancer Center
NCT05605522 TERMINATED
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
3B Pharmaceuticals GmbH
NCT07121829 TERMINATED
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT04634539 COMPLETED
Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
Jun Gong, MD
NCT05634525 WITHDRAWN
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
M.D. Anderson Cancer Center
NCT04580485 COMPLETED
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
NCT05432193 TERMINATED
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
NCT05788484 COMPLETED
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
NCT01351103 COMPLETED
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis Pharmaceuticals
NCT04292743 COMPLETED
Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma
Georgetown University
NCT05657418 TERMINATED
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
Shanghai Junshi Bioscience Co., Ltd.
NCT05440942 COMPLETED
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
Peter Hosein, MD
NCT04152018 TERMINATED
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
NCT02047500 TERMINATED
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
NCT04581343 COMPLETED
A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients
Pancreatic Cancer Action Network
NCT00954525 COMPLETED
Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT05383352 COMPLETED
A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
Ipsen
NCT04796948 COMPLETED
A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.
NCT04809766 TERMINATED
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Fred Hutchinson Cancer Center
NCT03825289 TERMINATED
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
University of Utah
NCT05940844 WITHDRAWN
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
NCT05737706 TERMINATED
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Mirati Therapeutics Inc.
NCT05494866 TERMINATED
A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
German Cancer Research Center
NCT03520790 TERMINATED
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
NCT05303090 COMPLETED
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
Fudan University
NCT04805307 COMPLETED
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
Keymed Biosciences Co.Ltd
NCT01638533 COMPLETED
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
NCT05631574 TERMINATED
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Biomea Fusion Inc.
NCT06538207 COMPLETED
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Ono Pharmaceutical Co., Ltd.
NCT04883775 COMPLETED
Study of a New Technique for Imaging Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT02672917 TERMINATED
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
BioNTech Research & Development, Inc.
NCT04916236 TERMINATED
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
The Netherlands Cancer Institute
NCT04703920 COMPLETED
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
University of Michigan Rogel Cancer Center
NCT06206876 WITHDRAWN
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
NCT02671890 TERMINATED
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer
Mayo Clinic
NCT04807972 TERMINATED
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
AbbVie
NCT04164069 COMPLETED
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Anne Noonan
NCT02643498 COMPLETED
A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT03549000 TERMINATED
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis Pharmaceuticals
NCT03086642 COMPLETED
Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
Karie D. Runcie, MD
NCT01010945 COMPLETED
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
OSI Pharmaceuticals
NCT05182112 COMPLETED
Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver
Memorial Sloan Kettering Cancer Center
NCT03960060 TERMINATED
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
Shanghai PerHum Therapeutics Co., Ltd.
NCT03087591 COMPLETED
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
Wake Forest University Health Sciences
NCT02791334 COMPLETED
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Eli Lilly and Company
NCT04672460 COMPLETED
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
NCT03716596 TERMINATED
SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT03517176 COMPLETED
CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
Lisata Therapeutics, Inc.
NCT03819387 COMPLETED
A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
Nitto BioPharma, Inc.
NCT03956056 TERMINATED
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Washington University School of Medicine
NCT05769959 TERMINATED
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Hoffmann-La Roche
NCT04400383 COMPLETED
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
CARsgen Therapeutics Co., Ltd.
NCT05484011 TERMINATED
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
HiberCell, Inc.
NCT03490669 COMPLETED
Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors
AstraZeneca
NCT01761240 COMPLETED
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
Morphotek
NCT03329950 COMPLETED
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
NCT04682431 TERMINATED
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ikena Oncology
NCT03373188 COMPLETED
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Emory University
NCT03878524 TERMINATED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
NCT04025216 TERMINATED
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Kite, A Gilead Company
NCT04803305 COMPLETED
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Pfizer
NCT04046887 TERMINATED
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
Patrick Joseph Loehrer Sr.
NCT01825603 COMPLETED
ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
University of Nebraska
NCT03454451 COMPLETED
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
NCT04299048 COMPLETED
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Pfizer
NCT03525392 TERMINATED
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Ipsen
NCT03095781 COMPLETED
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
Emory University
NCT03784677 COMPLETED
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT02231723 COMPLETED
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Sumitomo Pharma America, Inc.
NCT02498665 COMPLETED
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT04247126 COMPLETED
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
NCT06017323 WITHDRAWN
Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma
Georgetown University
NCT04721301 COMPLETED
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
University Hospital Heidelberg
NCT05650918 COMPLETED
MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)
Joachim Aerts, MD PhD
NCT03122106 TERMINATED
Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Washington University School of Medicine
NCT02897375 COMPLETED
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
NCT05395052 TERMINATED
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
NCT05043987 WITHDRAWN
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
Conjupro Biotherapeutics, Inc.
NCT00638612 COMPLETED
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
Candel Therapeutics, Inc.
NCT04050085 COMPLETED
SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
University of California, Davis
NCT01835041 COMPLETED
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Wake Forest University Health Sciences
NCT03829436 COMPLETED
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT04990037 COMPLETED
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Cantargia AB
NCT05431582 WITHDRAWN
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
NCT04193904 TERMINATED
A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
4D pharma plc
NCT02333188 COMPLETED
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
University of Chicago
NCT04799431 WITHDRAWN
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01420874 COMPLETED
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Barbara Ann Karmanos Cancer Institute
NCT03507452 COMPLETED
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
Bayer
NCT04542291 COMPLETED
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Washington University School of Medicine
NCT02930902 COMPLETED
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
NCT04430842 COMPLETED
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
NCT02873598 COMPLETED
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
University of Colorado, Denver
NCT03883919 COMPLETED
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Washington University School of Medicine
NCT02349867 COMPLETED
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
Virginia Commonwealth University
NCT00981162 COMPLETED
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Roswell Park Cancer Institute
NCT02588443 COMPLETED
Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Abramson Cancer Center at Penn Medicine
NCT02394535 COMPLETED
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
NCT04632199 WITHDRAWN
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
Ipsen
NCT04060342 TERMINATED
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
NCT01924260 COMPLETED
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Edward Kim
NCT02227940 COMPLETED
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
Roswell Park Cancer Institute
NCT01497392 COMPLETED
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Roswell Park Cancer Institute
NCT02451553 COMPLETED
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
University of Washington
NCT02514031 TERMINATED
ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer
University of Texas Southwestern Medical Center
NCT01918644 COMPLETED
Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer
University of Wisconsin, Madison
NCT03412799 COMPLETED
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Panbela Therapeutics, Inc.
NCT04131192 TERMINATED
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
Sunshine Lake Pharma Co., Ltd.
NCT02702986 COMPLETED
Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)
Universita di Verona
NCT03147768 COMPLETED
Laser Tissue Welding - Distal Pancreatectomy Sealing Study
Laser Tissue Welding, Inc.
NCT02646748 COMPLETED
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
NCT03300921 TERMINATED
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
NCT02526017 COMPLETED
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Five Prime Therapeutics, Inc.
NCT03281382 COMPLETED
Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer
Henry Ford Health System
NCT03985072 COMPLETED
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
Andes Biotechnologies
NCT00967577 COMPLETED
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Weill Medical College of Cornell University
NCT02947165 COMPLETED
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis Pharmaceuticals
NCT03319459 COMPLETED
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT03645148 COMPLETED
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer
Zhejiang Provincial People's Hospital
NCT01523808 COMPLETED
Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer
ERYtech Pharma
NCT02777710 COMPLETED
Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
Centre Leon Berard
NCT01510561 WITHDRAWN
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Gilead Sciences
NCT02138383 COMPLETED
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03316599 COMPLETED
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
Dana-Farber Cancer Institute
NCT02546531 COMPLETED
Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Washington University School of Medicine
NCT01335945 TERMINATED
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Boston Scientific Corporation
NCT02908451 TERMINATED
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
AbGenomics B.V Taiwan Branch
NCT02368860 COMPLETED
OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma
National Cancer Centre, Singapore
NCT04270929 WITHDRAWN
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
Roger Williams Medical Center
NCT02237157 COMPLETED
A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer
RenovoRx
NCT03205176 COMPLETED
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
AstraZeneca
NCT02608229 TERMINATED
BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Washington University School of Medicine
NCT02048384 COMPLETED
A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02155088 COMPLETED
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT02468557 TERMINATED
Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
Gilead Sciences
NCT02154737 COMPLETED
Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
Tony Reid, M.D., Ph.D.
NCT02259114 COMPLETED
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03207724 COMPLETED
Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia
Andrew Hendifar, MD
NCT02703571 TERMINATED
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01487785 COMPLETED
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Novartis Pharmaceuticals
NCT01576666 COMPLETED
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT03790423 COMPLETED
18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
Rigshospitalet, Denmark
NCT02757391 TERMINATED
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
M.D. Anderson Cancer Center
NCT02045602 COMPLETED
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
Theriva Biologics SL
NCT02101580 COMPLETED
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Polaris Group
NCT01385956 COMPLETED
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03925428 WITHDRAWN
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT01189929 COMPLETED
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
OncoMed Pharmaceuticals, Inc.
NCT02005315 COMPLETED
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
OncoMed Pharmaceuticals, Inc.
NCT02050178 COMPLETED
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
OncoMed Pharmaceuticals, Inc.
NCT01485744 COMPLETED
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
Massachusetts General Hospital
NCT02092948 COMPLETED
Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer
Jonsson Comprehensive Cancer Center
NCT01908478 COMPLETED
Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer
Cedars-Sinai Medical Center
NCT01803282 COMPLETED
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
NCT00739609 TERMINATED
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
NewLink Genetics Corporation
NCT01643499 COMPLETED
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
University of Chicago
NCT03286062 TERMINATED
VM110 in Detection of Microscopic Tumors: A Phase I Study
Fox Chase Cancer Center
NCT02681796 COMPLETED
Epidural Analgesia Use in Pancreatic Resections
Washington University School of Medicine
NCT01473940 COMPLETED
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Northwestern University
NCT00836407 COMPLETED
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01744353 COMPLETED
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
Brown University
NCT02576665 TERMINATED
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
NCT02559674 COMPLETED
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Altor BioScience
NCT03865563 WITHDRAWN
Selective Transvenous Chemoembolization of Primary Pancreatic Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03307148 COMPLETED
Stromal TARgeting for PAncreatic Cancer (STAR_PAC)
Barts & The London NHS Trust
NCT01488513 COMPLETED
ABC294640 in Treating Patients With Advanced Solid Tumors
RedHill Biopharma Limited
NCT03811652 COMPLETED
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
MedImmune LLC
NCT02465983 TERMINATED
Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
University of Pennsylvania
NCT02586987 COMPLETED
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
NCT02148549 COMPLETED
Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study
Wakayama Medical University
NCT02574663 COMPLETED
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
TG Therapeutics, Inc.
NCT02894944 COMPLETED
Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer
Seoul National University Hospital
NCT02734160 COMPLETED
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
NCT02707328 TERMINATED
Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
The Cooper Health System
NCT01739439 TERMINATED
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
Fox Chase Cancer Center
NCT02179970 COMPLETED
To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers
CCTU- Cancer Theme
NCT02283372 COMPLETED
Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Washington University School of Medicine
NCT02514421 COMPLETED
Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma
The University of Texas Health Science Center, Houston
NCT02581501 WITHDRAWN
Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer
Stamford Hospital
NCT00968604 WITHDRAWN
C-VISA BikDD: Liposome in Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
NCT01188785 COMPLETED
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas
Silenseed Ltd
NCT01537107 COMPLETED
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Mayo Clinic
NCT02868632 WITHDRAWN
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
NYU Langone Health
NCT02782182 TERMINATED
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
University of Chicago
NCT01984658 COMPLETED
A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients
CytoVac A/S
NCT01025882 TERMINATED
Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer
University of Texas Southwestern Medical Center
NCT02244489 TERMINATED
Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
Sierra Oncology LLC - a GSK company
NCT02548169 TERMINATED
Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer
Baylor Research Institute
NCT01839981 COMPLETED
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Wake Forest University Health Sciences
NCT01770132 COMPLETED
Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
John DeWitt
NCT02960594 COMPLETED
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
Inovio Pharmaceuticals
NCT02592395 WITHDRAWN
Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma
The University of Texas Health Science Center, Houston
NCT01833546 COMPLETED
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Merck KGaA, Darmstadt, Germany
NCT02045589 COMPLETED
A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer
Theriva Biologics SL
NCT01663272 COMPLETED
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
University of Michigan Rogel Cancer Center
NCT02620423 COMPLETED
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
NCT02191761 COMPLETED
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
Biosplice Therapeutics, Inc.
NCT00783172 TERMINATED
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
Milton S. Hershey Medical Center
NCT02650635 TERMINATED
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Mayo Clinic
NCT02166255 COMPLETED
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Wake Forest University Health Sciences
NCT01342224 COMPLETED
Immunochemoradiotherapy in Patients With Pancreatic Cancer
Providence Health & Services
NCT01822756 TERMINATED
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
Incyte Corporation
NCT01929941 TERMINATED
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Incyte Corporation
NCT01012362 TERMINATED
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT00703638 COMPLETED
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT00667082 COMPLETED
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
NCT02272738 COMPLETED
A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer
Osaka Medical Center for Cancer and Cardiovascular Diseases
NCT02106871 WITHDRAWN
Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer
The University of Texas Medical Branch, Galveston
NCT01897415 COMPLETED
Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer
University of Pennsylvania
NCT01783171 COMPLETED
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01764477 COMPLETED
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
Prism Pharma Co., Ltd.
NCT01191684 COMPLETED
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
City of Hope Medical Center
NCT02651727 TERMINATED
Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
Verastem, Inc.
NCT00987766 COMPLETED
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Vanderbilt-Ingram Cancer Center
NCT01386502 WITHDRAWN
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00654160 COMPLETED
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Mayo Clinic
NCT00882973 COMPLETED
Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer
Samyang Biopharmaceuticals Corporation
NCT01571024 COMPLETED
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT02567396 WITHDRAWN
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
NCT02174887 COMPLETED
Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer
Institut Paoli-Calmettes
NCT01893294 COMPLETED
Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer
Mayo Clinic
NCT00761345 COMPLETED
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
Fox Chase Cancer Center
NCT01198821 COMPLETED
Gem-TABS in Unresectable Pancreatic Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT01946646 TERMINATED
Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer
National Taiwan University Hospital
NCT02720666 COMPLETED
K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT01677962 COMPLETED
A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma
Medical University of South Carolina
NCT02210364 COMPLETED
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
PharmaMar
NCT01410968 COMPLETED
A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma
Carolyn Britten
NCT01335958 COMPLETED
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Genentech, Inc.
NCT01521325 COMPLETED
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Morphotek
NCT01935453 COMPLETED
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
OrienGene Biotechnology Ltd.
NCT00837135 WITHDRAWN
GI-4000 With Adoptive Transfer in Pancreatic Cancer
University of Pennsylvania
NCT00614653 COMPLETED
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
NCT01450046 COMPLETED
Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects
H. Lee Moffitt Cancer Center and Research Institute
NCT01446952 COMPLETED
Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects
H. Lee Moffitt Cancer Center and Research Institute
NCT01296763 COMPLETED
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01274455 COMPLETED
Gene Therapy of Pancreatic Ductal Adenocarcinoma
University Hospital, Toulouse
NCT01298401 COMPLETED
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
Radiation Therapy Oncology Group
NCT01098344 COMPLETED
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery
Cancer Research UK
NCT01674556 COMPLETED
Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer
Haukeland University Hospital
NCT00925769 COMPLETED
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Hoffmann-La Roche
NCT01050283 TERMINATED
A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)
Merck Sharp & Dohme LLC
NCT01954732 WITHDRAWN
Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
Case Comprehensive Cancer Center
NCT00735306 COMPLETED
Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
Duke University
NCT00983268 COMPLETED
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
Vanderbilt-Ingram Cancer Center
NCT01486329 COMPLETED
VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer
Vaximm GmbH
NCT02132403 TERMINATED
(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
University of Illinois at Chicago
NCT02159248 WITHDRAWN
Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
Orlando Health, Inc.
NCT02048943 WITHDRAWN
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Roswell Park Cancer Institute
NCT01131234 COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01834170 COMPLETED
EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer
University of Tehran
NCT01492907 COMPLETED
Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer
University of Minnesota
NCT01181245 COMPLETED
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Kyntra Bio
NCT01741597 WITHDRAWN
Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
City of Hope Medical Center
NCT01167816 TERMINATED
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
University of Oklahoma
NCT01025570 TERMINATED
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
University of California, San Francisco
NCT00878657 TERMINATED
Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer
Rutgers, The State University of New Jersey
NCT01233505 TERMINATED
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01145456 COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01192763 TERMINATED
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
National Cancer Institute (NCI)
NCT01282333 TERMINATED
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT01161186 COMPLETED
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
University of California, San Francisco
NCT01041235 COMPLETED
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Azaya Therapeutics, Inc.
NCT00556023 COMPLETED
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer
AstraZeneca
NCT01051284 COMPLETED
A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic Cancer
Georgetown University
NCT00626158 COMPLETED
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
University of California, San Francisco
NCT00909558 SUSPENDED
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
Envita Medical Center, Inc.
NCT07557394 NOT YET RECRUITING
A Prospective Non-randomized Controlled Interventional Study on the Effect of Shouhui Tongbian Capsules Combined With Pancreatin Enteric-coated Capsules on Pancreatic Exocrine Function in Patients After Curative Resection for Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT05634720 ACTIVE NOT RECRUITING
Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
Duke University
NCT07302841 NOT YET RECRUITING
Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT07262957 RECRUITING
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT04025840 ACTIVE NOT RECRUITING
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
Peking University First Hospital
NCT06099119 RECRUITING
Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.
Hospital Clinico Universitario de Santiago
NCT06779318 NOT YET RECRUITING
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
The First Affiliated Hospital with Nanjing Medical University
NCT05784311 RECRUITING
Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)
Leiden University Medical Center
NCT06368063 RECRUITING
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
Xi'an Jiaotong University
NCT06387368 NOT YET RECRUITING
Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer
Xi'an Jiaotong University
NCT05035147 RECRUITING
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT06199752 COMPLETED
Synergistic Immunomodulatory Effect of Synbiotics Pre and Postoperative Resection of Pancreatic Ductal Adenocarcinoma
Theodor Bilharz Research Institute
NCT04155008 TERMINATED
Nutrition and Pharmacological Algorithm for Oncology Patients Study
Montefiore Medical Center
NCT01887041 TERMINATED
Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer
Universitätsklinikum Hamburg-Eppendorf
NCT03891979 WITHDRAWN
Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
NYU Langone Health
NCT02570529 WITHDRAWN
Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy
Yonsei University
NCT01768988 TERMINATED
Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study
Parc de Salut Mar
NCT00920023 COMPLETED
Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
Massachusetts General Hospital
NCT00966277 COMPLETED
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
M.D. Anderson Cancer Center
NCT01041612 COMPLETED
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Taewoong Medical Co., Ltd.
NCT00854477 COMPLETED
Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma
Cambridge University Hospitals NHS Foundation Trust
NCT01256034 COMPLETED
Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
Chiba University
Full Pancreatic Cancer Pipeline
Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only